Bifidobacterium spp.

Generic Name: Bifidobacterium spp.

Drug Type: Biotech

Unique Ingredient Identifier: IO1WP3918D

Clinical Trials

Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level

Not Applicable

Completed

Conditions: Berberine Hydrochloride

Interventions: Drug: Berberine Hydrochloride group
Drug: placebo
Drug: Bifidobacterium group
Drug: Berberine Hydrochloride and Bifidobacterium group

First Posted Date: 2017-11-06

Last Posted Date: 2021-03-15

Lead Sponsor: Xijing Hospital

Target Recruit Count: 300

Registration Number: NCT03330184

BIFI-OBESE: Clinical Trial in Paediatric Obesity

Phase 4

Completed

Conditions: Obesity, Childhood

Interventions: Drug: Placebos
Drug: Bifidobacterium breve BR03 and Bifidobacterium breve B632

First Posted Date: 2017-08-25

Last Posted Date: 2018-01-11

Lead Sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita

Target Recruit Count: 100

Registration Number: NCT03261466

Locations: 🇮🇹
AOU Maggiore della Carità - Clinica Pediatrica - Ambulatorio di Auxologia ed Endocrinologia Pediatrica, Novara, Italy

NEOBIFI: Clinical Trial for the Prevention and/or Reduction of the Incidence of Colics in Infants

Phase 4

Completed

Conditions: Gut Microbiome
Probiotic
Colic, Infantile
Bifidobacterium Breve

Interventions: Drug: Placebos
Drug: Bifidobacterium breve BR03 and Bifidobacterium breve B632

First Posted Date: 2017-07-18

Last Posted Date: 2018-01-11

Lead Sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita

Target Recruit Count: 320

Registration Number: NCT03219931

Locations: 🇮🇹
AOU Maggiore della Carità - Clinica Pediatrica - Ambulatorio di Gastroenterologia Pediatrica, Novara, Italy

Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics

Phase 2

Completed

Conditions: Antibiotic-associated Diarrhea

Interventions: Biological: Bifidobacterium animalis subsp. lactis BB-12
Other: Control

First Posted Date: 2017-06-08

Last Posted Date: 2025-02-21

Lead Sponsor: Georgetown University

Target Recruit Count: 255

Registration Number: NCT03181516

Locations: 🇺🇸
Georgetown University Department of Family Medicine, Research Division, Washington, District of Columbia, United States

The Effects of a Synbiotic Addition on Eradication Therapy of Helicobacter Pylori Infection in Children

Not Applicable

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Amoxicillin Oral Tablet
Drug: Bifidobacterium Animalis Oral Product
Drug: Clarithromycin Oral Tablet
Drug: Omeprazole

First Posted Date: 2017-05-24

Last Posted Date: 2017-05-24

Lead Sponsor: Bulent Ecevit University

Target Recruit Count: 69

Registration Number: NCT03165253

Effectiveness of Bifidobacteria in Children Affected by Seasonal Allergic Rhinitis

Phase 3

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Bifidobacteria
Drug: placebo

First Posted Date: 2016-06-21

Last Posted Date: 2018-06-26

Lead Sponsor: University of Campania "Luigi Vanvitelli"

Target Recruit Count: 40

Registration Number: NCT02807064

Locations: 🇮🇹
Second University, Naples, Italy

Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders

Phase 4

Completed

Conditions: Dyspepsia Chronic
Irritable Bowel Syndrome

Interventions: Drug: Mixture of three Bifidobacteria

First Posted Date: 2015-10-02

Last Posted Date: 2015-10-02

Lead Sponsor: Federico II University

Target Recruit Count: 73

Registration Number: NCT02566876

Locations: 🇮🇹
University of Naples "Federico II" Italy, Naples, Italy

Cytokine Profile in Children With Celiac Disease

Phase 1

Completed

Conditions: Celiac Disease

Interventions: Drug: Placebo (for Bifidobacterium breve)
Drug: Bifidobacterium breve

First Posted Date: 2014-09-18

Last Posted Date: 2014-09-18

Lead Sponsor: University Medical Centre Maribor

Target Recruit Count: 66

Registration Number: NCT02244047

Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment

Phase 2

Withdrawn

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Bifidobacterium viable pharmaceutics
Drug: Berberine Hydrochloride

First Posted Date: 2014-03-11

Last Posted Date: 2018-11-14

Lead Sponsor: Xijing Hospital

Registration Number: NCT02084004

Locations: 🇨🇳
Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳
The 323rd Hospital of People's Liberation Army, Xi'an, Shaanxi, China
🇨🇳
Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China

and more 1 locations

Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment

Phase 2

Withdrawn

Conditions: Prediabetes

Interventions: Drug: Bifidobacterium viable pharmaceutics
Drug: Berberine Hydrochloride

First Posted Date: 2014-03-10

Last Posted Date: 2018-11-14

Lead Sponsor: Xijing Hospital

Registration Number: NCT02082756

Locations: 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an,, Shaanxi, China
🇨🇳
Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳
The 323rd Hospital of People's Liberation Army, Xi'an, Shaanxi, China

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy